Data & Analysis Core
数据
基本信息
- 批准号:10657451
- 负责人:
- 金额:$ 30.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressBiochemical MarkersBlindedChemopreventionChemopreventive AgentCirrhosisCitiesClinicalClinical ResearchComprehensive Cancer CenterDataData AnalysesData CollectionData LinkagesData SetDevelopmentDiabetes MellitusEarly DiagnosisEffectivenessElectronicsEnrollmentEnsureEpidemiologyEquipment and supply inventoriesEtiologyFunctional disorderFundingFutureGenetic MarkersGoalsHuman ResourcesIndividualInformaticsInformation TechnologyMachine LearningMalignant neoplasm of liverManualsMathematicsMedicineMetabolicMetabolic dysfunctionMetabolic syndromeMetforminMissionMonitorObesityParticipantPatientsPersonsPreventionPrevention strategyPrimary carcinoma of the liver cellsProcessProspective cohortProtocols documentationResearch DesignResearch PersonnelResource SharingResourcesRetrievalRetrospective cohortRisk FactorsRisk ReductionSamplingScienceServicesSiteSpecimenStatistical Data InterpretationStatistical MethodsStatistical ModelsSupport SystemSystemTechnologyTestingTexasThiazolidinedionesTranslational ResearchUnited States Department of Veterans AffairsUpdateVertebral columnWorkbiomarker developmentbiomarker discoverybiomarker validationcentral databasecohortcollegecomparativecostdashboarddata harmonizationdata managementdesignepidemiologic dataexperiencefatty liver diseasefollow-upmembermetabolic-associated fatty liver diseasemodels and simulationmortalitymultidimensional datanovel markeroperationparticipant enrollmentphenotypic biomarkerprofessorprogramsquality assurancerecruitresearch studyrisk stratificationskillsstatisticsstemsuccesssynergismtimelinetoolvalidation studiesweb platform
项目摘要
ABSTRACT— Data and Analysis Core
The Program Project (PP) overarching goal is to reduce the burden of hepatocellular carcinoma (HCC)-related
mortality. We will achieve this goal by enhancing the understanding of contemporary risk factors (e.g.,
phenotypic, biochemical, and genetic markers of metabolic dysfunction) and preventive strategies (e.g.,
chemoprevention, surveillance) for rapidly increasing HCC related to metabolic (dysfunction) associated fatty
liver disease (MAFLD). The PP includes three Projects; two shared resource cores, the Data and Analysis
Core (DAC) and the Biospecimen and Biomarker Development Core (BBDC); and the Administrative Core, all
with the shared mission of stemming the rising tide of MAFLD-HCC.
Central to this PP is leveraging and expanding our multicity, ongoing prospective cohort of persons with MAFLD-
related cirrhosis, as well as a retrospective cohort identified in the national Department of Veterans Affairs (VA)
datasets. The aims of the three projects require rigorous implementation of well-designed protocols for
coordination and implementation of patient enrollment and biospecimen and data collection. Further, they need
optimal, complete follow-up of patients with cirrhosis to determine if the participants developed HCC. The BBDC
requires support programs and systems to track samples between enrollment sites to identify and select
samples for testing related to specific projects. All three PP studies also require rigorous advanced methods
for statistical analyses and information technology. All these needs will be addressed by the DAC.
The goal of the DAC is to provide critical expertise and support in data management, coordination, statistics
and information technology for all projects in the PP. The Specific Aims of DAC are to provide the PP projects
and BDCC with (1) Management and coordination, including implementing and maintaining a Manual of
Operation (MOO) of the multicity, multisite prospective cohort; (2) Programming and systems support to
maintain central databases for PP Projects, track samples, design programs to monitor study data, and develop
electronic dashboards to ensure regulatory compliance and timely progress of PP Projects and Cores; (3)
Statistical expertise for programming, ongoing quality assurance, study design guidance, and analysis and
interpretation of data; and (4) Informatics technology to harmonize data collection efforts among PP
investigators and collaborators and to develop apps for users that interface with simulation models.
DAC members have extensive experience and expertise in the design and statistical analyses of variety of
study as well as continuity of skills, protocols and personnel related to the THCCC cohort. DAC will ensure
the all Projects and Cores achieve the overarching goal of reducing HCC related mortality.
摘要-数据和分析核心
该计划项目(PP)的总体目标是减少肝细胞癌(HCC)相关的负担。
mortality.我们将通过加强对当代风险因素的理解来实现这一目标(例如,
代谢功能障碍的表型、生物化学和遗传标记)和预防策略(例如,
与代谢(功能障碍)相关的脂肪肝相关的快速增加的HCC
肝病(MAFLD)。PP包括三个项目;两个共享资源核心,数据和分析
核心(DAC)和生物标本和生物标志物开发核心(BBDC);以及行政核心,所有
共同的使命是阻止MAFLD-HCC的上升趋势。
该PP的核心是利用和扩大我们的多城市,持续的MAFLD患者前瞻性队列-
相关肝硬化,以及在国家退伍军人事务部(VA)确定的回顾性队列
数据集。这三个项目的目标要求严格执行精心设计的协议,
协调和实施患者入组、生物样本和数据收集。此外,他们需要
对肝硬化患者进行最佳、完整的随访,以确定参与者是否发展为HCC。BBDC
需要支持程序和系统来跟踪入组研究中心之间的样本,以识别和选择
用于测试与特定项目相关的样品。所有三项PP研究也都需要严格的先进方法
用于统计分析和信息技术。所有这些需求都将由发援会解决。
发展援助委员会的目标是在数据管理、协调、统计、
和信息技术为所有项目的PP。DAC的具体目标是提供PP项目
(1)管理和协调,包括执行和维持一份《发展筹资问题手册》,
多城市、多地点前瞻性队列的运作;(2)方案编制和系统支助,
维护PP项目的中央数据库,跟踪样本,设计监控研究数据的程序,并开发
电子仪表板,以确保PP项目和核心的合规性和及时进展;(3)
编程、持续质量保证、研究设计指导和分析的统计专业知识,
数据解释;以及(4)信息技术,以协调参与方之间的数据收集工作
研究人员和合作者,并为用户开发与模拟模型接口的应用程序。
发展援助委员会成员在设计和统计分析各种
研究以及与THCCC队列相关的技能、协议和人员的连续性。DAC将确保
所有项目和核心都实现了降低肝癌相关死亡率的总体目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher I. Amos其他文献
Shared susceptibility variations in autoimmune diseases: a brief perspective on common issues
自身免疫性疾病的共同易感性变异:对常见问题的简要看法
- DOI:
10.1038/gene.2008.92 - 发表时间:
2009 - 期刊:
- 影响因子:5
- 作者:
M. Seldin;Christopher I. Amos - 通讯作者:
Christopher I. Amos
Hereditary medullary thyroid carcinoma: genetic annalysis of three related syndromes. Groupe d'Etude des Tumeurs a Calcitonine.
遗传性甲状腺髓样癌:三种相关综合征的遗传分析。
- DOI:
- 发表时间:
1989 - 期刊:
- 影响因子:0
- 作者:
Hagay Sobol;S. A. Narod;I. Schuffenecker;Christopher I. Amos;Ezekowitz Ra;Lenoir Gm - 通讯作者:
Lenoir Gm
Estimating the power of linkage analysis in hereditary breast cancer.
估计连锁分析在遗传性乳腺癌中的功效。
- DOI:
- 发表时间:
1990 - 期刊:
- 影响因子:9.8
- 作者:
S. A. Narod;Christopher I. Amos - 通讯作者:
Christopher I. Amos
Multi-ancestry GWAS meta-analyses of lung cancer reveal susceptibility loci and elucidate smoking-independent genetic risk
肺癌的多祖先全基因组关联研究荟萃分析揭示了易感位点并阐明了与吸烟无关的遗传风险
- DOI:
10.1038/s41467-024-52129-4 - 发表时间:
2024-10-04 - 期刊:
- 影响因子:15.700
- 作者:
Bryan R. Gorman;Sun-Gou Ji;Michael Francis;Anoop K. Sendamarai;Yunling Shi;Poornima Devineni;Uma Saxena;Elizabeth Partan;Andrea K. DeVito;Jinyoung Byun;Younghun Han;Xiangjun Xiao;Don D. Sin;Wim Timens;Jennifer Moser;Sumitra Muralidhar;Rachel Ramoni;Rayjean J. Hung;James D. McKay;Yohan Bossé;Ryan Sun;Christopher I. Amos;Saiju Pyarajan - 通讯作者:
Saiju Pyarajan
Uncovering shared genetic features between inflammatory bowel disease and systemic lupus erythematosus
- DOI:
10.1038/s41598-025-98991-0 - 发表时间:
2025-05-01 - 期刊:
- 影响因子:3.900
- 作者:
Vikram R. Shaw;Jinyoung Byun;Catherine Zhu;Rowland W. Pettit;Jeffrey M. Cohen;Younghun Han;Christopher I. Amos - 通讯作者:
Christopher I. Amos
Christopher I. Amos的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher I. Amos', 18)}}的其他基金
International Consortium for the Genetics of Biliary Tract Cancers Cholangiocarcinoma Genome Wide Association Study
国际胆道癌遗传学联盟胆管癌全基因组关联研究
- 批准号:
10608848 - 财政年份:2023
- 资助金额:
$ 30.42万 - 项目类别:
Optimizing colorectal cancer prevention: a multi-disciplinary, population-based investigation of serrated polyps using risk prediction and modeling
优化结直肠癌预防:利用风险预测和建模对锯齿状息肉进行多学科、基于人群的调查
- 批准号:
10436886 - 财政年份:2020
- 资助金额:
$ 30.42万 - 项目类别:
Optimizing colorectal cancer prevention: a multi-disciplinary, population-based investigation of serrated polyps using risk prediction and modeling
优化结直肠癌预防:利用风险预测和建模对锯齿状息肉进行多学科、基于人群的调查
- 批准号:
9916850 - 财政年份:2020
- 资助金额:
$ 30.42万 - 项目类别:
Optimizing colorectal cancer prevention: a multi-disciplinary, population-based investigation of serrated polyps using risk prediction and modeling
优化结直肠癌预防:利用风险预测和建模对锯齿状息肉进行多学科、基于人群的调查
- 批准号:
10650289 - 财政年份:2020
- 资助金额:
$ 30.42万 - 项目类别:
Optimizing colorectal cancer prevention: a multi-disciplinary, population-based investigation of serrated polyps using risk prediction and modeling
优化结直肠癌预防:利用风险预测和建模对锯齿状息肉进行多学科、基于人群的调查
- 批准号:
10207552 - 财政年份:2020
- 资助金额:
$ 30.42万 - 项目类别:
相似海外基金
Resting Concentrations of Bone Biochemical Markers in Adolescent Female Athletes of High-impact and
高冲击力和高强度青少年女运动员骨生化标志物的静息浓度
- 批准号:
564842-2021 - 财政年份:2021
- 资助金额:
$ 30.42万 - 项目类别:
University Undergraduate Student Research Awards
The utility of ultrasound and biochemical markers for the purpose of predicting cardiac failure in recipient's fetuses in twin-twin transfusion syndrome.
超声和生化标记物在预测双胎输血综合征受者胎儿心力衰竭中的应用。
- 批准号:
17K16875 - 财政年份:2017
- 资助金额:
$ 30.42万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
MICA: Phase II study of the impact of AZD4017 a selective 11beta-HSD1 inhibitor on biochemical markers of bone turnover in post-menopausal osteopaenia
MICA:选择性 11β-HSD1 抑制剂 AZD4017 对绝经后骨质疏松症骨转换生化标志物影响的 II 期研究
- 批准号:
MR/K015176/2 - 财政年份:2015
- 资助金额:
$ 30.42万 - 项目类别:
Research Grant
Development of biochemical markers for quality and/or quantity of child sleep
开发儿童睡眠质量和/或数量的生化标记物
- 批准号:
15K12721 - 财政年份:2015
- 资助金额:
$ 30.42万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
MICA: Phase II study of the impact of AZD4017 a selective 11beta-HSD1 inhibitor on biochemical markers of bone turnover in post-menopausal osteopaenia
MICA:选择性 11β-HSD1 抑制剂 AZD4017 对绝经后骨质疏松症骨转换生化标志物影响的 II 期研究
- 批准号:
MR/K015176/1 - 财政年份:2014
- 资助金额:
$ 30.42万 - 项目类别:
Research Grant
Development of assessment methodology on behaviors of water quality threatening algae in lakes considering their life cycle and using biochemical markers
考虑其生命周期并使用生化标记物开发威胁湖泊水质的藻类行为的评估方法
- 批准号:
25289151 - 财政年份:2013
- 资助金额:
$ 30.42万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Biochemical Markers of Bone Metabolism and Paget s Disease of Bone
骨代谢和佩吉特骨病的生化标志物
- 批准号:
G0801462/2 - 财政年份:2012
- 资助金额:
$ 30.42万 - 项目类别:
Research Grant
Evaluation for bone quality in jaw bone using biochemical markers of bone turnover
使用骨转换的生化标记物评估颌骨的骨质量
- 批准号:
23792296 - 财政年份:2011
- 资助金额:
$ 30.42万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Evaluation of pain experience in domestic fowl: associations between clinical symptoms biochemical markers and bird self-selection of analgesics
家禽疼痛体验的评估:临床症状生化标志物与家禽自我选择镇痛药之间的关联
- 批准号:
BB/G002738/1 - 财政年份:2011
- 资助金额:
$ 30.42万 - 项目类别:
Research Grant
Chronic oral graft-versus-host disease: clinical risk factors, biochemical markers of disease activity and novel therapeutics
慢性口腔移植物抗宿主病:临床危险因素、疾病活动的生化标志物和新疗法
- 批准号:
nhmrc : 1017351 - 财政年份:2011
- 资助金额:
$ 30.42万 - 项目类别:
Postgraduate Scholarships